TR200103688T2 - NK1 alıcı antagonisti olarak kristalin (2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2-metoksibenzil) amonyumklorit polimorfları. - Google Patents

NK1 alıcı antagonisti olarak kristalin (2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2-metoksibenzil) amonyumklorit polimorfları.

Info

Publication number
TR200103688T2
TR200103688T2 TR2001/03688T TR200103688T TR200103688T2 TR 200103688 T2 TR200103688 T2 TR 200103688T2 TR 2001/03688 T TR2001/03688 T TR 2001/03688T TR 200103688 T TR200103688 T TR 200103688T TR 200103688 T2 TR200103688 T2 TR 200103688T2
Authority
TR
Turkey
Prior art keywords
polymorphs
methoxybenzyl
aza
iso
oct
Prior art date
Application number
TR2001/03688T
Other languages
English (en)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Jon Gumkowski Michael
Joseph Muehlbauer David
Norris Timothy
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200103688T2 publication Critical patent/TR200103688T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

(2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2- metoksibenzil)amin diloridin dihidratin iki kristalin polimorf biçimi Biçim I ve Biçim II'dir. Söz konusu polimorflardan en az birini içeren farmasötik bilesim, kemoterapi gören hastalarda emesis tedavisi için formülasyon olusturmada avantajli bir biçimde dayaniklilik saglamaktadir. Söz konusu farmasötik bilesimin tercihen tablet ya da kapsül ile agiz yoluyla ya da damar içinden uygulanir. Ayni zamanda Biçim I ve Biçim II'nin yapimina yönelik bir yöntem de açiklanmaktadir.
TR2001/03688T 1999-06-22 2000-06-06 NK1 alıcı antagonisti olarak kristalin (2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2-metoksibenzil) amonyumklorit polimorfları. TR200103688T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22

Publications (1)

Publication Number Publication Date
TR200103688T2 true TR200103688T2 (tr) 2002-12-23

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03688T TR200103688T2 (tr) 1999-06-22 2000-06-06 NK1 alıcı antagonisti olarak kristalin (2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2-metoksibenzil) amonyumklorit polimorfları.

Country Status (35)

Country Link
US (1) US6262067B1 (tr)
EP (1) EP1187834A1 (tr)
JP (1) JP2003502425A (tr)
KR (1) KR20020030280A (tr)
CN (1) CN1390216A (tr)
AP (1) AP2001002367A0 (tr)
AR (1) AR024411A1 (tr)
AU (1) AU767336B2 (tr)
BG (1) BG106205A (tr)
BR (1) BR0011835A (tr)
CA (1) CA2375265A1 (tr)
CO (1) CO5190663A1 (tr)
CZ (1) CZ20014458A3 (tr)
DZ (1) DZ3055A1 (tr)
EA (1) EA004264B1 (tr)
EC (1) ECSP003538A (tr)
EE (1) EE200100698A (tr)
HR (1) HRP20010920A2 (tr)
HU (1) HUP0201694A3 (tr)
IL (1) IL146410A0 (tr)
IS (1) IS6161A (tr)
MA (1) MA26744A1 (tr)
MX (1) MXPA02000033A (tr)
NO (1) NO20016187D0 (tr)
NZ (1) NZ515348A (tr)
OA (1) OA11952A (tr)
PA (1) PA8496701A1 (tr)
PE (1) PE20010322A1 (tr)
PL (1) PL352899A1 (tr)
SK (1) SK18672001A3 (tr)
TN (1) TNSN00137A1 (tr)
TR (1) TR200103688T2 (tr)
UY (1) UY26211A1 (tr)
WO (1) WO2000078759A1 (tr)
ZA (1) ZA200110387B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
WO2004031191A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic spiroether derivatives as receptor antagonists
DE60324703D1 (de) 2002-12-11 2008-12-24 Taro Pharma Ind Barbitursäure derivaten.
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
WO2008066704A2 (en) * 2006-11-14 2008-06-05 Taro Pharmaceuticals North America, Inc. Method of improving bioavailability for non-sedating barbiturates
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
BR112021024330A2 (pt) * 2019-06-03 2022-01-11 Biotheryx Inc Sais cristalinos não higroscópicos de um composto de pirazol, e composições farmacêuticas e uso dos mesmos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
CA2102179C (en) * 1991-05-31 1998-10-27 Fumitaka Ito Quinuclidine derivatives
KR950704311A (ko) * 1992-11-12 1995-11-17 알렌 제이. 스피겔 물질 p 길항체로서의 퀴누클리딘 유도체(quinuclidine derivative as substance p antagonist)
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
PL352899A1 (en) 2003-09-22
TNSN00137A1 (fr) 2002-05-30
AU767336B2 (en) 2003-11-06
ECSP003538A (es) 2002-01-25
DZ3055A1 (fr) 2004-03-27
ZA200110387B (en) 2002-12-19
HRP20010920A2 (en) 2003-02-28
EP1187834A1 (en) 2002-03-20
WO2000078759A1 (en) 2000-12-28
UY26211A1 (es) 2001-01-31
EA004264B1 (ru) 2004-02-26
EA200101179A1 (ru) 2002-06-27
CA2375265A1 (en) 2000-12-28
EE200100698A (et) 2003-02-17
MXPA02000033A (es) 2002-07-02
AR024411A1 (es) 2002-10-02
PE20010322A1 (es) 2001-03-14
SK18672001A3 (sk) 2002-08-06
CN1390216A (zh) 2003-01-08
IS6161A (is) 2001-11-13
BG106205A (bg) 2002-07-31
US6262067B1 (en) 2001-07-17
MA26744A1 (fr) 2004-12-20
HUP0201694A2 (en) 2002-09-28
IL146410A0 (en) 2002-07-25
OA11952A (en) 2006-04-13
CO5190663A1 (es) 2002-08-29
JP2003502425A (ja) 2003-01-21
CZ20014458A3 (cs) 2002-03-13
BR0011835A (pt) 2002-03-05
NO20016187L (no) 2001-12-18
NZ515348A (en) 2003-07-25
PA8496701A1 (es) 2002-07-30
KR20020030280A (ko) 2002-04-24
AU4774500A (en) 2001-01-09
AP2001002367A0 (en) 2001-12-31
NO20016187D0 (no) 2001-12-18
HUP0201694A3 (en) 2002-10-28

Similar Documents

Publication Publication Date Title
HUP9902121A2 (hu) Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények
TR199801115T2 (tr) Kinazolin türevleri.
TR200103688T2 (tr) NK1 alıcı antagonisti olarak kristalin (2-benzihidril-1-aza-çift-döngülü [2,2,2]okt-3-il)-5-izo-propil-2-metoksibenzil) amonyumklorit polimorfları.
BRPI0610187A2 (pt) tablete dispersável ou um solvato ou sal farmaceuticamente aceitável do mesmo, e excipientes farmaceuticamente aceitáveis, processo para a preparação dos mesmos, e, uso de composto ou de um sal ou solvato farmaceuticamente aceitável do mesmo
DE69713152D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
KR920700033A (ko) 로라타딘, 이부프로펜 및 슈도에페드린을 함유하는 약제학적 조성물
TR200002853T2 (tr) Antitümör etkili indolil-3-glioksilik asit türevleri
DE69713148D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zusammensetzungen
NO972968L (no) Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler
MY119181A (en) Aryl pyrimidine derivatives
ATE236185T1 (de) Makrozyklische derivate von erythromycin a und b mit 13 ringatomen
HUP9701778A2 (hu) Raloxifen alkalmazása mellrák megelőzésére alkalmas gyógyszerkészítmény előállítására
TR200002506T2 (tr) S ile ikame edilmiş 11beta-benzaldoksim-estra-4,9-dien-karbonik asit tiolesterler, üretimleri için yöntem ve bu bileşimleri içeren farmasötik terkipler.
RS20050231A (en) Pyrrole derivatives as antimycobacterial compounds
HUP9900227A2 (hu) AII-receptor antagonisták új gyógyszerészeti felhasználása
DE69819166D1 (de) 8-substituierte-9h-1,3-dioxolo/4,5-h//2,3/benzodiazepin derivate als ampa/kainate-rezeptor-hemmer
BR0011125A (pt) Polimorfos de citrato de (2-benzidril-1-azabiciclo[2.2.2]oct-3-il)-(5-iso-propil-2-m etoxibenzil)-amina cristalino como antagonistas de receptor nk-1
BG106180A (en) Pharmaceutical composition containing sibutramine and orlistat
EA200100869A1 (ru) Кристаллическая форма эплеренона
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
AP9901559A0 (en) Tricyclic 3-keto derivatives of 6-0-methylerythromycin.
AP9801235A0 (en) Erythromycin derivatives.
Gorina et al. PLN-74809, a dual αvβ6/αvβ1, oral, selective integrin inhibitor, is well tolerated and reduces lung TGF-β activity in healthy volunteers
ES8707729A1 (es) Un procedimiento para la preparacion de hexahidroarilquinolizinas sustituidas.